{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:28:20Z","timestamp":1792758500898,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in adult- and juvenile-onset myositis longitudinal cohorts and investigated phenotypic differences in myositis patients with AMA. We screened sera from myositis patients including 619 adult- and 371 juvenile-onset dermatomyositis (DM, JDM), polymyositis (PM, JPM), inclusion body myositis (IBM), or amyopathic DM patients and from healthy controls, including 164 adults and 92 children, for AMA by ELISA. Clinical characteristics were compared between myositis patients with and without AMA. AMA were present in 5% of adult myositis patients (16 of 216 DM, 10 of 222 PM, 4 of 140 IBM, 1 of 19 amyopathic DM), 1% of juvenile myositis patients (3 of 302 JDM, 1 of 25 JPM), and 1% of both adult and juvenile healthy controls. In patients with adult-onset myositis, AMA were associated with persistent muscle weakness, Raynaud\u2019s phenomenon, dysphagia, and cardiomyopathy. Adult myositis patients with AMA may have more severe or treatment refractory disease, as they more frequently received glucocorticoids and intravenous immunoglobulin. In juvenile myositis, children with AMA often had falling episodes and dysphagia, but no other clinical features or medications were significantly associated with AMA. AMA are present in 5% of adult myositis patients and associated with cardiomyopathy, dysphagia, and other signs of severe disease. The prevalence of AMA is not increased in patients with juvenile myositis compared to age-matched healthy controls. Our data suggest that the presence of AMA in adult myositis patients should prompt screening for cardiac and swallowing involvement.\n<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Approximately 5% of a large North American cohort of adult myositis patients have anti-mitochondrial autoantibodies.<\/jats:italic><jats:italic>\u2022 Adults with anti-mitochondrial autoantibodies often have chronic weakness, Raynaud\u2019s, dysphagia, cardiomyopathy, and more severe disease.<\/jats:italic><jats:italic>\u2022 Anti-mitochondrial autoantibodies are rare in juvenile myositis and not associated with a specific clinical phenotype.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s10067-021-05730-7","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T20:05:40Z","timestamp":1618344340000},"page":"4095-4100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-9958","authenticated-orcid":false,"given":"Sara E.","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Casal-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima","family":"Albayda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie J.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Johns Hopkins Myositis Center Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan","family":"Michelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tiniakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonye K.","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"9631","key":"5730_CR1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371(9631):2201\u20132212. https:\/\/doi.org\/10.1016\/S0140-6736(08)60955-1","journal-title":"Lancet"},{"issue":"1","key":"5730_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hep.28859","volume":"65","author":"G Dahlqvist","year":"2017","unstructured":"Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouill\u00e8res O, Poupon R, Johanet C, Corpechot C, the French network of Immunology Laboratories (2017) Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 65(1):152\u2013163. https:\/\/doi.org\/10.1002\/hep.28859","journal-title":"Hepatology"},{"issue":"4","key":"5730_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","volume":"47","author":"J Albayda","year":"2018","unstructured":"Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L (2018) Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47(4):552\u2013556. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.06.004","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"5730_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jbspin.2017.04.004","volume":"85","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Mariampillai K, Allenbach Y, Charuel JL, Musset L, Benveniste O (2018) Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine 85(3):375\u2013376. https:\/\/doi.org\/10.1016\/j.jbspin.2017.04.004","journal-title":"Joint Bone Spine"},{"issue":"7","key":"5730_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344\u2013347. https:\/\/doi.org\/10.1056\/NEJM197502132920706","journal-title":"N Engl J Med"},{"issue":"5","key":"5730_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (Nov 1995) Inclusion body myositis and myopathies. Ann Neurol 38(5):705\u2013713. https:\/\/doi.org\/10.1002\/ana.410380504","journal-title":"Ann Neurol"},{"issue":"19","key":"5730_CR7","doi-asserted-by":"publisher","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez I et al (2019) More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology 93(19):e1768\u2013e1777. https:\/\/doi.org\/10.1212\/WNL.0000000000008443","journal-title":"Neurology"},{"issue":"1","key":"5730_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","volume":"92","author":"M Shah","year":"2013","unstructured":"Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG, with the Childhood Myositis Heterogeneity Collaborative Study Group (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25\u201341. https:\/\/doi.org\/10.1097\/MD.0b013e31827f264d","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"5730_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","volume":"48","author":"T Kishi","year":"2018","unstructured":"Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group (2018) Medications received by patients with juvenile dermatomyositis. Semin Arthritis Rheum 48(3):513\u2013522. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.016","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5730_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3899\/jrheum.141443","volume":"42","author":"I Pinal-Fernandez","year":"2015","unstructured":"Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL (2015) The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42(8):1448\u20131454. https:\/\/doi.org\/10.3899\/jrheum.141443","journal-title":"J Rheumatol"},{"issue":"1","key":"5730_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.26731","volume":"61","author":"S Minamiyama","year":"2020","unstructured":"Minamiyama S, Ueda S, Nakashima R, Yamakado H, Sakato Y, Yamashita H, Sawamoto N, Fujimoto R, Nishino I, Urushitani M, Mimori T, Takahashi R (2020) Thigh muscle MRI findings in myopathy associated with anti-mitochondrial antibody. Muscle Nerve 61(1):81\u201387. https:\/\/doi.org\/10.1002\/mus.26731","journal-title":"Muscle Nerve"},{"issue":"7","key":"5730_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/01.res.84.7.840","volume":"84","author":"KE Loke","year":"1999","unstructured":"Loke KE et al (1999) Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 84(7):840\u2013845. https:\/\/doi.org\/10.1161\/01.res.84.7.840","journal-title":"Circ Res"},{"issue":"1","key":"5730_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/cvr\/cvq195","volume":"88","author":"SM Davidson","year":"2010","unstructured":"Davidson SM (2010) Endothelial mitochondria and heart disease. Cardiovasc Res 88(1):58\u201366. https:\/\/doi.org\/10.1093\/cvr\/cvq195","journal-title":"Cardiovasc Res"},{"issue":"10","key":"5730_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/art.1780361020","volume":"36","author":"J Varga","year":"1993","unstructured":"Varga J, Heiman-Patterson T, Munoz S, Love LA (1993) Myopathy with mitochondrial alterations in patients with primary biliary cirrhosis and antimitochondrial antibodies. Arthritis Rheum 36(10):1468\u20131475. https:\/\/doi.org\/10.1002\/art.1780361020","journal-title":"Arthritis Rheum"},{"key":"5730_CR15","doi-asserted-by":"publisher","unstructured":"Sabbagh S et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004","DOI":"10.1136\/annrheumdis-2018-215004"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05730-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05730-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05730-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T21:57:32Z","timestamp":1632520652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05730-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5730"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05730-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}